Stock 9SO SOLASIA PHARMA K.K.
Add to a list
To use this feature you must be a member
Log inSign up

Solasia Pharma K.K. Share Price Deutsche Boerse AG

Equities

9SO

JP3436500007

Pharmaceuticals

Delayed Deutsche Boerse AG
Other stock markets
 12:47:47 21/05/2024 pm IST 		5-day change 1st Jan Change
0.14 EUR 0.00% Intraday chart for Solasia Pharma K.K. 0.00% -47.76%
15/05 Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024 CI
04/03 Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 165.7Cr 1.06Cr 97.75L 88Cr Sales 2025 * 171.7Cr 1.1Cr 1.01Cr 92Cr Capitalization 491.57Cr 3.15Cr 2.9Cr 262.03Cr
Net income 2024 * -54Cr -34.45L -31.74L -29Cr Net income 2025 * -93Cr -59.3L -54.62L -49Cr EV / Sales 2024 * 2.87 x
Net cash position 2024 * 16Cr 10.31L 9L 8.58Cr Net Debt 2025 * 63Cr 40.15L 36.99L 33Cr EV / Sales 2025 * 3.23 x
P/E ratio 2024 *
-8.73 x
P/E ratio 2025 *
-5.97 x
Employees 24
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.69%
More Fundamentals * Assessed data

Chart Solasia Pharma K.K.

Dynamic Chart

Latest news about Solasia Pharma K.K.

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024 CI
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited CI
Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond CI
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited CI
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains MT
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma K.K.(TSE:4597) dropped from S&P Global BMI Index CI
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Teams Up with WEP Clinical to Supply Anti-Cancer Injection in Europe MT
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program CI
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023 CI
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study MT
More news

Press releases Solasia Pharma K.K.

Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin AQ
Solasia Announces Launch of Darvias® in Japan BU
Solasia Pharma K K : Business Overview of Pipeline Products (first six months of the Fiscal Year Ending December 31, 2022) PU
Solasia Pharma K K : Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (under IFRS) PU
Solasia Pharma K K : Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin) PU
More press releases

News in other languages on Solasia Pharma K.K.

Solasia gibt Einführung von Darvias® in Japan bekannt
Solasia anuncia el lanzamiento de Darvias® en Japón
Solasia Pharma: DARVIAS® als Injektion mit 135 mg (generischer Name: DARINAPARSIN/Entwicklungscode: SP-02) in Japan zugelassen
Solasia Pharma: DARVIAS® Inyección de 135 mg (Nombre genérico: DARINAPARSINA /Código de desarrollo: SP-02) Aprobado en Japón
Solasia Pharma K K :  Solasia gibt die Einreichung eines neuen Zulassungsantrags für das Krebsmedikament DARINAPARSIN zur Behandlung von peripherem T-Zell-Lymphom in Japan bekannt
More news

Quotes and Performance

Current month+3.70%
1 month+6.06%
3 months-30.69%
6 months-36.94%
Current year-47.76%
More quotes

Highs and lows

1 week
0.13
Extreme 0.134
0.15
1 month
0.13
Extreme 0.13
0.16
Current year
0.13
Extreme 0.13
0.28
1 year
0.13
Extreme 0.13
0.42
3 years
0.13
Extreme 0.13
1.22
5 years
0.13
Extreme 0.13
1.83
10 years
0.13
Extreme 0.13
5.09
More quotes

Managers and Directors - Solasia Pharma K.K.

Managers TitleAgeSince
Yoshihiro Arai CEO
 Chief Executive Officer 63 01/07/01
Koji Shinozaki FOU
 Founder - 01/06/01
Toshio Miyashita DFI
 Director of Finance/CFO 56 01/14/01
Members of the board TitleAgeSince
Yiu Kwan Lau BRD
 Director/Board Member 69 01/14/01
Yoshihiro Arai CEO
 Chief Executive Officer 63 01/07/01
Toshio Miyashita DFI
 Director of Finance/CFO 56 01/14/01
More insiders

Quotes

Date Price Change
21/24/21 0.14 0.00%
20/24/20 0.14 +4.48%
17/24/17 0.134 0.00%
16/24/16 0.134 -8.22%
15/24/15 0.146 +4.29%

Delayed Quote Deutsche Boerse AG, May 21, 2024 at 12:47 pm IST

More quotes

Company Profile

Solasia Pharma K.K. is a Japan-based pharmaceutical company. The Company is mainly engaged in the development, sale, importing and exporting of pharmaceutical products targeting commercialization in Japan, China and other Asian countries. It focuses on commercializing assets in the oncology/hematology field, by developing products licensed from western pharmaceutical and biotech companies. The Company's main products include SP-01 Granisetron Transdermal Delivery System (Sancuso), SP-02 Darinaparsin (Zinapar, ZIO-101, and SP-03 Oral Medical Device (episil oral liquid).
Sector
Pharmaceuticals
Calendar
14/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Solasia Pharma K.K.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
27 JPY
Average target price
100 JPY
Spread / Average Target
+270.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
-3.15% 8.97TCr
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+2.50% 4.13TCr
BIOGEN INC. Stock Biogen Inc.
-12.45% 3.37TCr
UCB Stock UCB
+62.74% 2.61TCr
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-20.74% 1.46TCr
INCYTE CORPORATION Stock Incyte Corporation
-9.11% 1.28TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.34% 1.17TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.92% 1.15TCr
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.27% 892.43Cr
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 4597 Stock
  4. 9SO Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW